Edwards Lifesciences (NYSE:EW) Updates Q2 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its second quarter earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.67-0.71 for the period, compared to the consensus earnings per share estimate of $0.70. The company issued revenue guidance of $1.62-1.70 billion, compared to the consensus revenue estimate of $1.65 billion. Edwards Lifesciences also updated its FY 2024 guidance to 2.700-2.800 EPS.

Edwards Lifesciences Price Performance

NYSE EW traded down $1.58 during trading on Friday, reaching $86.43. 4,979,943 shares of the company traded hands, compared to its average volume of 2,883,164. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The stock’s 50 day moving average price is $90.28 and its two-hundred day moving average price is $78.85. The company has a market cap of $52.02 billion, a price-to-earnings ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. Edwards Lifesciences has a 1-year low of $60.57 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. As a group, analysts anticipate that Edwards Lifesciences will post 2.76 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on EW shares. Citigroup boosted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a neutral rating in a research report on Wednesday, April 3rd. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an overweight rating in a research report on Friday. StockNews.com cut shares of Edwards Lifesciences from a buy rating to a hold rating in a research report on Wednesday, March 20th. Stifel Nicolaus boosted their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a hold rating in a research report on Friday. Finally, Mizuho upped their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a buy rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $93.33.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the completion of the sale, the vice president now owns 39,503 shares of the company’s stock, valued at $3,390,542.49. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,004 shares of company stock valued at $17,166,254. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.